IRDye700Dx (Maleimide)
Based on 1 Customer Validation
IRDye700Dx Maleimide is a Photosensitizer. When conjugated with HER2 Affibody and activated by near-infrared light, IRDye700Dx Maleimide induces death in HER2-positive breast cancer cells without causing damage to HER2-negative breast cancer cells.
For research use only. We do not sell to patients.
- Purity : 94.16%
- Formula: C76H99N13Na4O26S6Si3
- Molecular Weight:1979.28
-
Storage:
-80°C, protect from light
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Description
In Vitro
Incubation of HER2 Affibody with IRDye700Dx Maleimide (5-fold molar excess; 2 h) successfully yields purified HER2 Affibody-IR700Dye conjugates[1].
HER2 Affibody-IR700Dye conjugate (0.1-0.3 μM; 2 h) induces selective cytotoxicity in HER2-positive SK-BR3, MDA-MB361 and JIMT1 breast cancer cells, but exerts no such effect in HER2-negative MCF7 breast cancer cells when used for near-infrared photoimmunotherapy (NIR-PIT)[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
Appearance Solid
-
Molecular Weight 1979.28
-
Formula C76H99N13Na4O26S6Si3
-
Color Light blue to blue
-
SMILES
C[Si](CCC[N+](CCC[S](=O)(O[Na])=O)(CCC[S](=O)(O[Na])=O)CCC[S](=O)([O-])=O)(C)[O-][Si+4]12([N-]3C4=NC(C5=CC=CC=C65)=[N]1C6=NC7=C(C=CC=C8)C8=C9[N-]27)([N](C%10=N9)=C(C%11=CC=CC=C%10%11)N=C3C%12=CC=CC(OCCCOC(NCCCCCC(NCCN%13C(C=CC%13=O)=O)=O)=O)=C4%12)[O-][Si](C)(C)CCC[N+](CCC[S](=O)(O[Na])=O)(CCC[S](=O)(O[Na])=O)CCC[S](=O)([O-])=O
-
Shipping
Shipping with dry ice.
-
Storage
-80°C, protect from light
Protocols
-
Breast Cancer Modeling
Breast cancer is a heterogeneous cancer, and it has been distinguished into four subtypes: luminal A, luminal B, HER2-positive and basal-like. Molecular mutations, epigenetic alterations, hormone exposure and immune microenvironment are related to the progression of breast cancer.
Purity & Documentation
-
Data Sheet (279 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
IRDye700Dx (Maleimide) Related Classifications
HY-D2309 Related Classifications
Powered by Bioz
Keywords
- IRDye700Dx (Maleimide)
- Fluorescent Dye
- Photosensitizer
- brain metastatic breast cancer cells
- mouse models
- HER2 low-expressing breast cancer cells
- HER2-positive breast cancer cells
- HER2 Affibody
- trastuzumab-resistant breast cancer cells
- HER2-negative breast cancer cells
- SK-BR3 breast cancer cells
- near-infrared light
- trastuzumab
- Inhibitor
- inhibitor
- inhibit